- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | BIO-GENE TECHNOLOGY LTD: Appointment of CFO and Joint Company Secretary | - | ASX | ||
| 05.03. | BIO-GENE TECHNOLOGY LTD: Investor Webinar - FY24 Half Year Review | 1 | ASX | ||
| 25.02. | BIO-GENE TECHNOLOGY LTD: Appendix 4D - Half Year Accounts - 31 December 2023 | - | ASX | ||
| 28.01. | BIO-GENE TECHNOLOGY LTD: Appendix 4C - 31 December 2023 | - | ASX | ||
| 19.01. | BIO-GENE TECHNOLOGY LTD: Bio-Gene Receives R&D Tax Incentive | 1 | ASX | ||
| 13.12.23 | BIO-GENE TECHNOLOGY LTD: Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan | 1 | ASX | ||
| 13.12.23 | BIO-GENE TECHNOLOGY LTD: BGT Corporate Presentation | 1 | ASX | ||
| 07.12.23 | BIO-GENE TECHNOLOGY LTD: Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan | 3 | ASX | ||
| 01.12.23 | BIO-GENE TECHNOLOGY LTD: Bio-Gene to Present at Automic Invest 2023 Conference | 1 | ASX | ||
| 27.11.23 | BIO-GENE TECHNOLOGY LTD: Becoming a substantial holder | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Change of Director's Interest Notice - P May | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Change of Director's Interest Notice - C Ramsey | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Change of Director's Interest Notice - T Grogan | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Change of Director's Interest Notice - A Guthrie | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Change of Director's Interest Notice - A Ding | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Notification of cessation of securities - BGT | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Cleansing Statement | - | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Application for quotation of securities - BGT | - | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: Results of Meeting | 1 | ASX | ||
| 23.11.23 | BIO-GENE TECHNOLOGY LTD: BGT 2023AGM - CEO's Presentation | - | ASX |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,030 | -20,53 % | Paion Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| NANOREPRO | 1,705 | -2,29 % | EQS-News: NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen | EQS-News: NanoRepro AG
/ Schlagwort(e): Aktienrückkauf
NanoRepro AG: Veröffentlichung von Kapitalmarktinformationen
15.04.2024 / 09:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| 4SC | 8,280 | -3,72 % | 4SC will Therapie schnell in den klinischen Einsatz bringen | 4SC stellt auf einer Konferenz in Pasadena (Kalifornien, USA) Daten einer zulassungsrelevanten RESMAIN-Studie zu Resminostat vor. Es gibt demnach einen klinischen Nachweis, dass Resminostat (Kinselby)... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 1,718 | -3,05 % | Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying | ||
| BRAIN BIOTECH | 3,000 | 0,00 % | EQS-News: BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Sonstiges
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
16.04.2024 / 11:20 CET/CEST
Für... ► Artikel lesen | |
| BIOXXMED | 0,452 | -16,30 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Shelly Group, Valneva | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| AAP IMPLANTATE | 0,785 | 0,00 % | EQS-Adhoc: aap Implantate AG: aap Verschiebung der Veröffentlichung des Konzernabschlusses 2023 aufgrund personeller Engpässe | EQS-Ad-hoc: aap Implantate AG / Schlagwort(e): Jahresbericht
aap Implantate AG: aap Verschiebung der Veröffentlichung des Konzernabschlusses 2023 aufgrund personeller Engpässe
17.04.2024... ► Artikel lesen | |
| CLINUVEL | 9,115 | +0,33 % | CLINUVEL PHARMACEUTICALS LIMITED: Change to executive management | ||
| SANGAMO THERAPEUTICS | 0,480 | -0,95 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| SCORPIUS | 0,152 | +0,66 % | Scorpius Holdings, Inc.: Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 | Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023 Achieves Record Backlog of $9.3 Million... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,820 | -1,62 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
| BIO-GATE | 1,000 | 0,00 % | BioGate Precision Medicine Corp.: A Global Milestone in Innovative Pancreatic Cancer Therapy | Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy... ► Artikel lesen | |
| EDITAS MEDICINE | 5,240 | -0,42 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates | Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates... ► Artikel lesen | |
| TREVENA | 0,349 | -6,19 % | Trevena, Inc.: Trevena Awarded OLINVYK Agreement with Premier, Inc. | CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| EVOLVA | 0,983 | -3,87 % | Adhoc: Evolva Holding SA: Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected | Evolva Holding SA / Key word(s): AGMEGM
Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction... ► Artikel lesen |
BIO-GENE TECHNOLOGY LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
